VivoSim Labs Inc Stock Price, News & Analysis

VIVS Nasdaq

Welcome to our dedicated page for VivoSim Labs news (Ticker: VIVS), a resource for investors and traders seeking the latest updates and insights on VivoSim Labs stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VivoSim Labs's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VivoSim Labs's position in the market.

05/13/2025 08:05 AM

News

VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference

Rhea-AI Summary

VivoSim Labs (NASDAQ: VIVS) has received a prestigious "Poster of Distinction" award at the Digestive Disease Week Conference for its NAMkind™ intestinal platform. The platform represents a breakthrough in non-animal testing methods (NAM) for drug development, particularly for inflammatory bowel disease (IBD) treatments. The system uses primary human cells from both healthy donors and IBD patients to create models that accurately reflect intestinal biology and disease characteristics. This development aligns with the FDA's recent announcement to phase out animal testing requirements, positioning VivoSim to disrupt the >$10B animal testing market. The company's technology combines AI-based computational modeling with human organ model-based lab testing, aiming to provide more predictive and ethically sound solutions for pharmaceutical testing, particularly in areas like chemotherapy-related intestinal side effects.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.57%

VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference

Rhea-AI Summary

VivoSim Labs (NASDAQ: VIVS) presented groundbreaking results for its NAMkind™ liver toxicology prediction platform at the Digestive Disease Week Conference. The platform demonstrated 87.5% sensitivity in predicting liver toxicity cases and 100% specificity in avoiding false positives. NAMkind™ uses physical organoid wet lab models from human donor cells and is developing AI-enhanced in silico predictions. This advancement aligns with FDA's recent initiative to phase out animal testing, targeting a >$10B market. VivoSim claims its technology could reduce drug development costs by 50% and significantly decrease late-stage clinical trial failures due to liver toxicity. The company's platform also addresses intestinal toxicity issues in cancer treatments, potentially improving chemotherapy dosing and reducing side effects.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.56%

VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market

Rhea-AI Summary

VivoSim Labs (Nasdaq: VIVS) has emerged from stealth mode to revolutionize drug development with its NAMkind™ services suite, following FDA's announcement to phase out animal testing requirements. The company's technology focuses on liver and intestinal toxicology using human organ model-based lab testing and AI-powered computational modeling.

The company aims to disrupt the $10B+ animal testing market with more predictive and ethically sound methods. VivoSim's liver model has demonstrated industry-best correlation rates with known clinical failures, and the company projects it can reduce clinical trial failures due to liver toxicity by 50% or more.

The technology utilizes physical organoid wet lab models created from human donor cells, combined with AI-driven predictions for liver toxicity, intestinal toxicity, and permeability. VivoSim believes its approach could reduce drug development costs per approved drug by 50% across the industry.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of VivoSim Labs (VIVS)?

The current stock price of VivoSim Labs (VIVS) is $1.85 as of August 1, 2025.

What is the market cap of VivoSim Labs (VIVS)?

The market cap of VivoSim Labs (VIVS) is approximately 5.2M.

VivoSim Labs Inc

Nasdaq:VIVS

VIVS Rankings

N/A Ranked by Market Cap

N/A Ranked by Dividends

VIVS Stock Data

Market Cap 5.23M

Float 2.57M

Sector Biological Products, (no Disgnostic Substances)

City SAN DIEGO